TABLE 1.
Baseline demographics
| Characteristic | Randomized treatment sequence a | Overall (n = 12) | |
|---|---|---|---|
| AB (n = 6) | BA (n = 6) | ||
| Sex, n (%) | |||
| Female | 1 (17) | 1 (17) | 2 (17) |
| Male | 5 (83) | 5 (83) | 10 (83) |
| Race, n (%) | |||
| Asian | 1 (17) | 0 (0) | 1 (8) |
| Black or African American | 1 (17) | 0 (0) | 1 (8) |
| Black or African American, White | 1 (17) | 0 (0) | 1 (8) |
| White | 3 (50) | 6 (100) | 9 (75) |
| Ethnicity, n (%) | |||
| Not Hispanic or Latino | 6 (100) | 6 (100) | 12 (100) |
| Age, years b | |||
| Mean (SD) | 36.7 (13.5) | 38.0 (8.1) | 37.3 (10.6) |
| Median (range) | 40.0 (21–52) | 39.5 (24–48) | 39.5 (21–52) |
| BMI, kg/m2 | |||
| Mean (SD) | 25.2 (2.4) | 26.8 (1.8) | 26.0 (2.2) |
| Median (range) | 24.9 (22.3–28.6) | 26.7 (24.8–29.1) | 25.7 (22.3–29.1) |
Abbreviations: BMI, body mass index; SD, standard deviation.
a
Treatment sequence AB: Participants received a single oral dose of trazpiroben 25 mg. After a 7‐day washout period, participants received a single oral dose of trazpiroben 25 mg immediately after a single 30‐min intravenous infusion of rifampin 600 mg. Treatment sequence BA: Participants received a single oral dose of trazpiroben 25 mg immediately after a single 30‐min intravenous infusion of rifampin 600 mg. After a 7‐day washout period, participants received a single oral dose of trazpiroben 25 mg.
b
Age as recorded on the case report form.